---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041586"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:38:35.215325+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aeglea closes Spyre asset acquisition, raises $210M, sells pegzilarginase, reports Q2 loss

## Summary
- Acquired Spyre's IBD pipeline (α4β7 and TL1A) for stock; raised $210M gross via Series A preferred private placement.
- Sold pegzilarginase rights to Immedica for $15M upfront + up to $100M milestones; net proceeds to CVR holders.
- Cash and equivalents $236.7M at June 30, including $210M financing; Q2 net loss $217.1M from acquisition-related charges.
- Net loss includes $130.5M acquired IPR&D expense and $58.2M forward contract liability expense.
- Expect SPY001 FIH study in H1 2024; SPY002 FIH study in H2 2024; healthy volunteer data by end-2024 / H1 2025.

## SEC filing metadata
- accession: 0000950170-23-041586
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000095017023041586/0000950170-23-041586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000095017023041586/agle-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041586
- JSON: https://secwatch.observer/filing/0000950170-23-041586.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041586.txt

## Key facts
- Earnings Releases
  Spyre Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 11, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000095017023041586/0000950170-23-041586-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.